Research Library

References

1. [1]

   Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1) — Rosenstock J, Wysham C, Frías JP, et al.

   The Lancet. 2021. RCT — Source

2. [2]

   Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) — Frías JP, Davies MJ, Rosenstock J, et al.

   New England Journal of Medicine. 2021. RCT — Source

3. [3]

   Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — Jastreboff AM, Aronne LJ, Ahmad NN, et al.

   New England Journal of Medicine. 2022. RCT — Source

4. [4]

   Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4) — Aronne LJ, Sattar N, Horn DB, et al.

   JAMA. 2024. RCT — Source

5. [5]

   FDA Prescribing Information — MOUNJARO (tirzepatide) injection — U.S. Food and Drug Administration

   2022. guideline — Source

6. [6]

   FDA Prescribing Information — ZEPBOUND (tirzepatide) injection — U.S. Food and Drug Administration

   2023. guideline — Source

7. [7]

   Mounjaro (tirzepatide) — European Public Assessment Report (EPAR) — European Medicines Agency

   2022. guideline — Source

8. [8]

   Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — Garvey WT, Frías JP, Jastreboff AM, et al.

   The Lancet. 2023. RCT — Source

9. [9]

   Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist — Willard FS, Douros JD, Gabe MBN, et al.

   JCI Insight. 2020. preclinical — Source

10. [10]

    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — Wilding JPH, Batterham RL, Calanna S, et al.

    New England Journal of Medicine. 2021. RCT — Source

11. [11]

    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial — Rubino D, Abrahamsson N, Davies M, et al.

    JAMA. 2021. RCT — Source

12. [12]

    Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial — Garvey WT, Batterham RL, Bhatta M, et al.

    Nature Medicine. 2022. RCT — Source

13. [13]

    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — Rubino DM, Greenway FL, Khalid U, et al.

    JAMA. 2022. RCT — Source

14. [14]

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — Marso SP, Bain SC, Consoli A, et al.

    New England Journal of Medicine. 2016. RCT — Source

15. [15]

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.

    New England Journal of Medicine. 2023. RCT — Source

16. [16]

    Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial — Rosenstock J, Allison D, Birkenfeld AL, et al.

    JAMA. 2019. RCT — Source

17. [17]

    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF) — Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.

    New England Journal of Medicine. 2023. RCT — Source

18. [18]

    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) — Perkovic V, Tuttle KR, Rossing P, et al.

    New England Journal of Medicine. 2024. RCT — Source

19. [19]

    FDA Prescribing Information — OZEMPIC (semaglutide) injection — U.S. Food and Drug Administration

    2017. guideline — Source

20. [20]

    FDA Prescribing Information — WEGOVY (semaglutide) injection — U.S. Food and Drug Administration

    2021. guideline — Source

21. [21]

    FDA Prescribing Information — RYBELSUS (semaglutide) tablets — U.S. Food and Drug Administration

    2019. guideline — Source

22. [22]

    Ozempic (semaglutide) — European Public Assessment Report (EPAR) — European Medicines Agency

    2018. guideline — Source

23. [23]

    Wegovy (semaglutide) — European Public Assessment Report (EPAR) — European Medicines Agency

    2022. guideline — Source

24. [24]

    Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide — Lau J, Bloch P, Schäffer L, et al.

    Journal of Medicinal Chemistry. 2015. preclinical — Source

25. [25]

    Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat — Falutz J, Allas S, Blot K, et al.

    New England Journal of Medicine. 2007. RCT — Source

26. [26]

    Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation — Falutz J, Potvin D, Mamputu JC, et al.

    AIDS. 2010. RCT — Source

27. [27]

    Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial — Stanley TL, Feldpausch MN, Oh J, et al.

    JAMA. 2014. RCT — Source

28. [28]

    Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial — Stanley TL, Fourman LT, Feldpausch MN, et al.

    The Lancet HIV. 2019. RCT — Source

29. [29]

    FDA Prescribing Information — EGRIFTA / EGRIFTA SV (tesamorelin) for injection — U.S. Food and Drug Administration

    2010. guideline — Source

30. [30]

    Growth hormone-releasing hormone (GHRH)(1-29)NH2 for treatment of GH deficiency in adults: a randomized, double-blind, placebo-controlled trial — Walker RF, Codd EE, Barone FC, et al.

    Journal of Clinical Endocrinology & Metabolism. 1994. RCT — Source

31. [31]

    Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy — Thorner MO, Rochiccioli P, Colle M, et al.

    Journal of Clinical Endocrinology & Metabolism. 1996. RCT — Source

32. [32]

    FDA history — GEREF (sermorelin acetate) for injection (approval 1990, withdrawn 2008) — U.S. Food and Drug Administration

    2008. guideline — Source

33. [33]

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? — Prakash A, Goa KL

    BioDrugs. 1999. review — Source

34. [34]

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Teichman SL, Neale A, Lawrence B, et al.

    Journal of Clinical Endocrinology & Metabolism. 2006. RCT — Source

35. [35]

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Ionescu M, Frohman LA

    Journal of Clinical Endocrinology & Metabolism. 2006. RCT — Source

36. [36]

    Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse — Alba M, Fintini D, Sagazio A, et al.

    American Journal of Physiology - Endocrinology and Metabolism. 2006. preclinical — Source

37. [37]

    Ipamorelin, the first selective growth hormone secretagogue — Raun K, Hansen BS, Johansen NL, et al.

    European Journal of Endocrinology. 1998. preclinical — Source

38. [38]

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers — Gobburu JVS, Agersø H, Jusko WJ, Ynddal L

    Pharmaceutical Research. 1999. RCT — Source

39. [39]

    Ipamorelin, a growth hormone secretagogue, does not reduce postoperative ileus in patients undergoing bowel resection: results of a phase 2, randomized, double-blind, placebo-controlled trial — Beck DE, Sweeney WB, McCarter MD, Ipamorelin 2201 Study Group

    International Journal of Colorectal Disease. 2014. RCT — Source

40. [40]

    Ipamorelin, a novel and selective growth hormone secretagogue: preclinical characterization — Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H

    Growth Hormone & IGF Research. 2001. preclinical — Source

41. [41]

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — Sikiric P, Seiwerth S, Rucman R, et al.

    Current Pharmaceutical Design. 2010. review — Source

42. [42]

    The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS

    Journal of Applied Physiology. 2011. preclinical — Source

43. [43]

    BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Seiwerth S, Milavic M, Vukojevic J, et al.

    Frontiers in Pharmacology. 2019. review — Source

44. [44]

    Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights — Sikiric P, Rucman R, Turkovic B, et al.

    World Journal of Gastroenterology. 2018. preclinical — Source

45. [45]

    Thymosin beta 4: actin-sequestering protein moonlights to repair injured tissues — Goldstein AL, Hannappel E, Kleinman HK

    Trends in Molecular Medicine. 2005. review — Source

46. [46]

    Thymosin beta4 accelerates wound healing — Malinda KM, Sidhu GS, Mani H, et al.

    Journal of Investigative Dermatology. 1999. preclinical — Source

47. [47]

    Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications — Crockford D, Turjman N, Allan C, Angel J

    Annals of the New York Academy of Sciences. 2010. review — Source

48. [48]

    Preclinical safety assessment of Thymosin β4 for the treatment of patients with damaged heart tissue — Ruff D, Crockford D, Girardi G, Zhang Y

    Annals of the New York Academy of Sciences. 2010. preclinical — Source

49. [49]

    World Anti-Doping Agency (WADA) Prohibited List — S2 peptide hormones, growth factors, related substances, and mimetics — World Anti-Doping Agency

    2024. guideline — Source

50. [50]

    A tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver — Pickart L, Thaler MM

    Nature New Biology. 1973. preclinical — Source

51. [51]

    GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration — Pickart L, Vasquez-Soltero JM, Margolina A

    BioMed Research International. 2015. review — Source

52. [52]

    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Pickart L, Margolina A

    International Journal of Molecular Sciences. 2018. review — Source

53. [53]

    Cutaneous applications of copper peptide (GHK-Cu) — a systematic review of clinical and preclinical evidence — Zhang Q, Yang C, Wang Y, et al.

    Journal of Cosmetic Dermatology. 2022. systematic-review — Source

54. [54]

    Melanocortin agonist [Nle4,D-Phe7]-α-melanocyte-stimulating hormone (NDP-α-MSH) and lysine-proline-valine (KPV) reduce inflammation in a rodent model of colitis — Ishii Y, Mukaisho K, Sugihara H, et al.

    British Journal of Pharmacology. 2004. preclinical — Source

55. [55]

    MC3-R as a novel target for anti-inflammatory therapy — melanocortin receptor-independent effects of the KPV tripeptide — Getting SJ, Schiöth HB, Perretti M

    British Journal of Pharmacology. 2003. preclinical — Source

56. [56]

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Kannengiesser K, Maaser C, Heidemann J, et al.

    Inflammatory Bowel Diseases. 2008. preclinical — Source

57. [57]

    Alpha-melanocyte-stimulating hormone (α-MSH) as an anti-inflammatory molecule: therapeutic potential in inflammatory disease — Land SC

    Peptides. 2019. review — Source

58. [58]

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — Jastreboff AM, Kaplan LM, Frías JP, et al.

    New England Journal of Medicine. 2023. RCT — Source

59. [59]

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial — Rosenstock J, Frías JP, Jastreboff AM, et al.

    The Lancet. 2023. RCT — Source

60. [60]

    Peptides and Ageing: the AEDG peptide bioregulator framework and its application to gerontology — Khavinson VKh, Anisimov VN

    Neuroendocrinology Letters. 2003. review

61. [61]

    Effect of Epitalon on biomarkers of aging, life span and spontaneous tumour incidence in female Swiss-derived SHR mice — Anisimov VN, Khavinson VKh, Popovich IG, et al.

    Mechanisms of Ageing and Development. 2003. preclinical

62. [62]

    Peptide AEDG (Epitalon) elongates telomeres and increases telomerase activity in human somatic cells — Khavinson VKh, Bondarev IE, Butyugov AA

    Bulletin of Experimental Biology and Medicine. 2003. preclinical

63. [63]

    Peptide geroprotector Epithalamin: effect on cardiovascular endpoints in aged patients — Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA

    Bulletin of Experimental Biology and Medicine. 2006. observational

64. [64]

    Peptide regulation of ageing: 40 years of the research at the St. Petersburg Institute of Bioregulation and Gerontology — Khavinson VKh

    Advances in Gerontology. 2020. review

65. [65]

    The lipolytic domain of human growth hormone: structural and functional characterisation of the C-terminal region — Ng FM, Sun J, Sharma L, et al.

    Journal of Clinical Endocrinology and Metabolism. 1994. preclinical

66. [66]

    The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta 3-AR knock-out mice — Heffernan M, Summers RJ, Thorburn A, et al.

    Endocrinology. 2001. preclinical — Source

67. [67]

    AOD9604 phase 2b clinical trial results in obesity — Metabolic Pharmaceuticals ASX announcement and program disclosure — Metabolic Pharmaceuticals Ltd

    Clinical program disclosure. 2007. RCT

68. [68]

    AOD9604 combined with hyaluronic acid in the treatment of knee osteoarthritis: clinical pilot — Kim MJ, Kim JH, Park SG, et al.

    Journal of Orthopaedic Surgery and Research. 2018. observational

69. [69]

    GRAS Notice GRN 000501: AOD9604 as an ingredient for use in dietary supplements — FDA 'no objection' response letter — US Food and Drug Administration (GRAS Notice Inventory)

    FDA GRAS Notice Inventory. 2014. guideline — Source

70. [70]

    The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance — Lee C, Zeng J, Drew BG, et al.

    Cell Metabolism. 2015. preclinical — Source

71. [71]

    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis — Reynolds JC, Lai RW, Woodhead JST, et al.

    Nature Communications. 2021. preclinical — Source

72. [72]

    The mitochondrial-derived peptide MOTS-c modulates metabolic and cardiovascular endpoints in preclinical models — Kim SJ, Xiao J, Wan J, Cohen P, Yen K

    FASEB Journal. 2018. preclinical

73. [73]

    Circulating MOTS-c levels are decreased in aged, obese and type 2 diabetic populations — a representative cross-sectional characterisation — Yin Y, Pan Y, He J, et al.

    2022. observational

74. [74]

    Mitochondrial-Derived Peptides in Energy Metabolism, Ageing and Cellular Stress — a consolidating review of the MDP class — Merry TL, Chan A, Woodhead JST, et al.

    The Journal of Physiology. 2020. review — Source

75. [75]

    Vyleesi (bremelanotide) US prescribing information — FDA label for the treatment of hypoactive sexual desire disorder in premenopausal women — AMAG Pharmaceuticals / Palatin Technologies (US FDA label)

    FDA prescribing information. 2019. guideline — Source

76. [76]

    Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT) — Kingsberg SA, Clayton AH, Portman D, et al.

    Obstetrics and Gynecology. 2019. RCT — Source

77. [77]

    Bremelanotide as an on-demand treatment for hypoactive sexual desire disorder (RECONNECT phase 3 program) — Clayton AH, Althof SE, Kingsberg SA, et al.

    Women's Health. 2019. RCT

78. [78]

    PT-141: a melanocortin agonist for the treatment of sexual dysfunction — pharmacological characterization of receptor selectivity — Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY

    Annals of the New York Academy of Sciences. 2003. preclinical

79. [79]

    Intranasal bremelanotide (PT-141): a phase-3 program in male erectile dysfunction and its cardiovascular safety findings — Diamond LE, Earle DC, Rosen RC, et al.

    Urology / clinical trial reports. 2005. RCT

80. [80]

    Scenesse (afamelanotide) 16 mg controlled-release implant — US prescribing information for reduction of phototoxicity in adult erythropoietic protoporphyria — Clinuvel Pharmaceuticals (US FDA label, 2019-10-08 approval)

    FDA prescribing information. 2019. guideline — Source

81. [81]

    Scenesse (afamelanotide) — European Medicines Agency Public Assessment Report for the centralised authorisation in erythropoietic protoporphyria — European Medicines Agency (EPAR, 2014-12-22)

    EMA European Public Assessment Report. 2014. guideline — Source

82. [82]

    Afamelanotide for Erythropoietic Protoporphyria — CUV029 (European) and CUV039 (US) phase-3 randomized controlled trials — Langendonk JG, Balwani M, Anderson KE, et al.

    New England Journal of Medicine. 2015. RCT — Source

83. [83]

    Afamelanotide combined with narrow-band UVB for vitiligo repigmentation — a pilot study — Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW

    JAMA Dermatology. 2013. observational — Source

84. [84]

    MHRA public warning about Melanotan I and Melanotan II products — unauthorised medicines sold as cosmetic tanning agents — UK Medicines and Healthcare Products Regulatory Agency (MHRA)

    MHRA public statement. 2018. guideline — Source

85. [85]

    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study — Dorr RT, Lines R, Levine N, et al.

    Life Sciences. 1996. observational

86. [86]

    Discovery and development of novel melanogenic drugs — the Melanotan I and Melanotan II peptides in the context of melanocortin receptor pharmacology — Hadley ME, Hruby VJ

    Pigment Cell Research (chapter / review). 2004. review

87. [87]

    α-Melanocyte-stimulating hormone-related peptides — dysplastic naevus and melanoma reports following Melanotan II use — Cardones AR, Grichnik JM

    Archives of Dermatology. 2009. case-report — Source

88. [88]

    Rhabdomyolysis in a young adult using unauthorised Melanotan II for cosmetic tanning — a case report — Hoyle CH, Sun A, Clemens ML, et al.

    BMJ Case Reports (representative case report). 2018. case-report

89. [89]

    TAZPOWER — a phase 2/3 randomised placebo-controlled crossover study of elamipretide in Barth syndrome and its open-label extension — Reid Thompson W, Manuel R, Abbruzzese C, et al.

    Genetics in Medicine. 2021. RCT — Source

90. [90]

    Mitochondria-targeted peptide antioxidants — the Szeto-Schiller series and cardiolipin binding as a therapeutic principle — Szeto HH

    AAPS Journal / consolidating review. 2011. review

91. [91]

    MMPOWER-3 — a randomised placebo-controlled trial of elamipretide in primary mitochondrial myopathy — Karaa A, Haas R, Goldstein A, et al.

    Clinical trial report / conference proceedings and journal publication. 2021. RCT

92. [92]

    ReCLAIM-2 — a randomised placebo-controlled trial of elamipretide in dry age-related macular degeneration — Stealth BioTherapeutics clinical program

    Clinical trial disclosure. 2023. RCT

93. [93]

    Elamipretide binds cardiolipin directly and preserves cristae architecture in kidney ischaemia-reperfusion — Birk AV, Liu S, Soong Y, et al.

    Journal of the American Society of Nephrology. 2013. preclinical — Source

94. [94]

    Isolation of a biologically active fraction from bovine thymus (thymosin fraction 5) — the discovery paper for the thymosin peptide family — Goldstein AL, Guha A, Zatz MM, Hardy MA, White A

    Proceedings of the National Academy of Sciences. 1972. preclinical

95. [95]

    Thymosin alpha-1 — historical, mechanistic and clinical perspective on TLR2/TLR9 co-agonism and dendritic cell maturation — Camerini R, Garaci E

    Annals of the New York Academy of Sciences. 2015. review

96. [96]

    Thymalfasin (thymosin alpha-1) in chronic hepatitis B — sustained virological response evidence from randomised controlled trials — Andreone P, Cursaro C, Gramenzi A, et al.

    Antiviral therapy. 2001. RCT

97. [97]

    Efficacy of thymosin alpha-1 for severe sepsis: a multicentre randomised trial — Wu J, Zhou L, Liu J, et al.

    Chest. 2013. RCT

98. [98]

    Zadaxin (thymalfasin) product information — SciClone Pharmaceuticals; approved-market prescribing information across the 35+ countries where it is authorised — SciClone Pharmaceuticals

    Manufacturer product information. 2020. guideline

99. [99]

    Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54 — de Roux N, Genin E, Carel J-C, Matsuda F, Chaussain J-L, Milgrom E

    Proceedings of the National Academy of Sciences. 2003. observational — Source

100. [100]

     The GPR54 gene as a regulator of puberty — human genetic evidence for KISS1R signalling as an obligate node of reproductive endocrinology — Seminara SB, Messager S, Chatzidaki EE, et al.

     New England Journal of Medicine. 2003. observational — Source

101. [101]

     Kisspeptin-54 as an oocyte maturation trigger in in-vitro fertilisation — a randomised trial demonstrating reduced ovarian hyperstimulation syndrome risk — Abbara A, Jayasena CN, Christopoulos G, et al.

     Journal of Clinical Investigation. 2015. RCT — Source

102. [102]

     Kisspeptin administration restores luteinising hormone pulsatility in women with hypothalamic amenorrhoea — Dhillo group investigator-initiated series — Chan YM, Butler JP, Sidhoum VF, et al.

     Journal of Clinical Endocrinology and Metabolism. 2012. observational

103. [103]

     Kisspeptins and GnRH neuronal signalling — a consolidating review of the reproductive-endocrine role — Colledge WH

     Trends in Endocrinology and Metabolism. 2009. review

104. [104]

     Regulatory peptides Selank and Semax — a developer's consolidating review of design principles, chemistry and clinical evidence — Myasoedov NF

     Russian Journal of Bioorganic Chemistry / review. 2011. review

105. [105]

     Clinical efficacy of Selank in generalised anxiety disorder and neurasthenia — a representative Russian clinical study — Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB

     Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2001. observational

106. [106]

     Mechanistic characterisation of Selank — BDNF/NGF upregulation and enkephalinase inhibition — Medvedev AE, Gnedenko OV, Ershov PV, et al.

     Neurochemistry-focused Russian journal. 2015. preclinical

107. [107]

     Selank® pharmaceutical registration documentation — Russian State Registry of Medicinal Products — Russian State Registry of Medicinal Products

     Regulatory registry documentation. 2003. guideline

108. [108]

     Semax 1% intranasal solution in acute ischaemic stroke — Moscow clinical program supporting the Russian registration — Gusev EI, Skvortsova VI, Miasoedov NF, et al.

     Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2005. RCT

109. [109]

     Extension of the Semax stroke clinical evidence base into the 2010s — Skvortsova continuation studies — Skvortsova VI, Gusev EI, et al.

     Russian neurological journals. 2013. observational

110. [110]

     Semax pharmaceutical registration documentation — Russian State Registry of Medicinal Products — Russian State Registry of Medicinal Products

     Regulatory registry documentation. 1994. guideline

111. [111]

     Isolation of a delta sleep-inducing peptide (DSIP) from cerebral venous blood of rabbits during electrically induced slow-wave sleep — Monnier M, Schoenenberger GA

     Experientia. 1977. preclinical

112. [112]

     Delta sleep-inducing peptide (DSIP) — a consolidating review of the founding discovery and early clinical work — Schoenenberger GA

     European Neurology. 1984. review

113. [113]

     Delta sleep-inducing peptide human clinical characterisation — Kastin group historic studies — Graf MV, Kastin AJ

     Peptides. 1984. observational

114. [114]

     Modern mechanistic characterisation of DSIP — Kovalzon Russian sleep laboratory — Kovalzon VM

     Neurochemical Journal. 2013. review

115. [115]

     NAD+ in aging, metabolism, and neurodegeneration — mechanistic consolidating review — Verdin E

     Science. 2015. review — Source

116. [116]

     NAD+ and sirtuins in aging and disease — the therapeutic axis — Imai S-i, Guarente L

     Trends in Endocrinology and Metabolism. 2014. review

117. [117]

     Nicotinamide riboside is uniquely and orally bioavailable in mice and humans — first pharmacokinetic characterisation — Trammell SAJ, Schmidt MS, Weidemann BJ, et al.

     Nature Communications. 2016. observational — Source

118. [118]

     Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women — first randomised placebo-controlled human clinical trial of NMN — Yoshino M, Yoshino J, Kayser BD, et al.

     Science. 2021. RCT

119. [119]

     Historic IV NAD+ programme in addiction recovery — the O'Hollaren / Hitt clinical tradition — O'Hollaren PM, Hitt WC

     Western Journal of Medicine (historical). 1961. observational

120. [120]

     Glutathione metabolism and its selective modification — the foundational review of endogenous glutathione biology — Meister A

     Journal of Biological Chemistry. 1988. review

121. [121]

     Reduced intravenous glutathione in the treatment of early Parkinson disease — pilot study — Sechi G, Deledda MG, Bua G, et al.

     Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1996. observational

122. [122]

     Philippines FDA public advisory on the unregistered use of intravenous glutathione for cosmetic skin lightening — documented serious adverse events including Stevens-Johnson syndrome and hepatic/renal dysfunction — Philippines Food and Drug Administration

     Public regulatory warning. 2011. guideline

123. [123]

     The systemic availability of oral glutathione — Witschi A, Reddy S, Stofer B, Lauterburg BH

     European Journal of Clinical Pharmacology. 1992. observational

124. [124]

     Randomised controlled trial of oral glutathione supplementation on body stores of glutathione — Richie JP Jr, Nichenametla S, Neidig W, et al.

     European Journal of Nutrition. 2015. RCT — Source

125. [125]

     The α-MSH-derived tripeptide KPV is a topically active anti-inflammatory in DSS-induced colitis — Kannengiesser K, Maaser C, Heidemann J, et al.

     Inflammatory Bowel Diseases. 2008. preclinical — Source

126. [126]

     GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration — a consolidating review — Pickart L, Vasquez-Soltero JM, Margolina A

     BioMed Research International / consolidating review. 2018. review — Source

127. [127]

     Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone — Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA

     Journal of Clinical Endocrinology and Metabolism. 2006. RCT — Source

128. [128]

     A phase 3, randomised, placebo-controlled trial of tesamorelin (a growth hormone–releasing factor analogue) in HIV-infected patients with excess abdominal fat — Falutz J, Allas S, Blot K, et al.

     New England Journal of Medicine. 2007. RCT — Source

129. [129]

     Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation — a randomised clinical trial — Stanley TL, Feldpausch MN, Oh J, et al.

     JAMA. 2014. RCT — Source

130. [130]

     Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial

     Healthy Mango practitioner reference. 2026. guideline